PENSACOLA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- A U.S. District Court Special Master in the talc multidistrict litigation (MDL) against Johnson & Johnson (J&J) entered an Opinion, reaffirming that plaintiffs may present expert testimony supporting general causation to the jury. Specifically, Special Master, Hon. L. Wolfson, former Chief Judge for the District of New Jersey, greenlighted the admissibility of expert testimony supporting that the perineal use of talc can cause ovarian cancer. Throughout her ...

December is the season for fortune-tellers, investment oracles, and self-proclaimed market prophets. We are in January; the new year has already started, and I am already late. Analyst's Disclosure: I/we have a beneficial long position in the shares of TRRSF, TSU:CA, PLMR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any ...

Core Viewpoint - The Vanguard Short-Term Treasury Index Fund ETF Shares (VGSH) may see benefits in 2026 if employment conditions deteriorate and the Federal Reserve decides to cut interest rates again [1] Group 1 - The ETF is positioned to potentially gain from a favorable price channel under adverse employment conditions [1]

Core Viewpoint - Asian stocks experienced a mostly positive trend following President Trump's decision to retract his tariff threats against European countries, which were in opposition to his Greenland acquisition proposal [1] Group 1 - The retraction of tariff threats by President Trump has contributed to a more favorable market sentiment in Asia [1] - The resistance from European countries regarding the Greenland plan was a significant factor influencing the tariff discussions [1]

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting with competent advisors before making any financial decisions, particularly in the context of investments in complex instruments like cryptocurrencies and CFDs [1]. Group 1 - The website provides general news, personal analysis, and opinions, as well as materials from third parties for educational and research purposes [1]. - It explicitly states that the information should not be interpreted as a recommendation or advice for any financial actions, including investments or purchases [1]. - The accuracy and reliability of the information are not guaranteed, and users are advised to consider their individual financial situations before relying on the content [1]. Group 2 - The website includes information about cryptocurrencies, CFDs, and other financial instruments, highlighting their complexity and the high risk of losing money associated with them [1]. - Users are encouraged to conduct their own research and fully understand the workings and risks of any financial instruments before investing [1].

Core Viewpoint - Steppe Gold Ltd. has provided a corporate update highlighting increased gold production and sales, along with significant financial agreements including a bond extension and a royalty buyback option agreement [1][2][3]. Production and Sales - In the fourth quarter of 2025, Steppe Gold produced 29,280 ounces of gold, exceeding the updated guidance of 23,000 ounces [2] - The unaudited gold sales for the same quarter were 37,357 ounces, leading to a total unaudited production and sales of approximately 76,000 ounces for the full year [2] Bond Extension - Steppe Gold's subsidiary, Boroo Gold LLC, has agreed to extend the maturity date of outstanding intercompany bonds from December 31, 2025, to December 31, 2026 [3] - The Board of Directors unanimously determined that this bond extension is in the best interest of the Company, based on recommendations from a special committee of independent directors [3][8] Terms of Bond Amendment - The bond amendment maintains all existing terms and conditions, with no changes to outstanding principal amounts, interest rates, or accrued interest [4] - The bond extension is classified as a "related party transaction" under Multilateral Instrument 61-101, with Steppe Gold relying on exemptions from formal valuation and minority approval requirements [5][10] Royalty Buyback Option Agreement - Steppe Gold has entered into a royalty buyback option agreement with Boroo Singapore regarding the Alturas gold project in Chile [6] - The agreement grants Steppe Gold a call option to repurchase a 0.25% net smelter return royalty, which can be exercised during a 30-day period starting November 7, 2029, for a payment of US$7.5 million [7][8] Related Party Transaction - The royalty buyback option agreement is also considered a "related party transaction" under Multilateral Instrument 61-101, with Steppe Gold again relying on exemptions from formal valuation and minority approval requirements [9][10]

Core Viewpoint - Corvus Pharmaceuticals, Inc. has announced an upsized underwritten public offering of 7,900,677 shares at a price of $22.15 per share, aiming to raise approximately $175.0 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 1,185,101 shares at the public offering price [1]. - The expected closing date for the offering is around January 23, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes, which may encompass capital expenditures and research and development for various clinical trials, including Phase 3 T cell lymphoma and Phase 2 trials for atopic dermatitis, hidradenitis suppurativa, and asthma [2]. Group 3: Underwriters - Jefferies and Goldman Sachs & Co. LLC are serving as lead book-running managers for the offering, with Mizuho as the bookrunner and Ladenburg Thalmann & Co. Inc. as a co-manager [3]. Group 4: Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for various immune diseases and cancers. The lead product candidate is soquelitinib, currently in a Phase 3 trial for relapsed/refractory PTCL and a Phase 1 trial for atopic dermatitis [6].

Group 1 - Seven Hills Realty Trust (SEVN) shares have declined nearly 30% in 2025 due to Federal Reserve easing impacting net interest margins, leading to a reduction in its distribution [2] - The company is part of a portfolio managed by Simplified Asset Management, which focuses on small and mid-cap stocks with significant insider purchases [2] Group 2 - The Insiders Forum portfolio aims to outperform the Russell 2000 benchmark over time, consisting of 12-25 top stocks across various sectors [2]

Investors applauded the bank's loan growth and surging profits.ServisFirst Bancshares (SFBS +14.58%) jumped on Wednesday after the Alabama-based bank holding company announced strong fourth-quarter results. By the close of trading, ServisFirst's stock price was up more than 14%. ServisFirst's solid operating performanceServisFirst's deposits rose by 5% year over year to $675.6 million, while its loans increased by 12% to $384.9 million.The bank's net interest margin, an important profitability metric for le ...

Core Insights - The article discusses the positive momentum and potential upside for Collegium Pharmaceutical (COLL) following its acquisition of BDSI, highlighting the company's growth trajectory since late 2022 [1]. Company Overview - Collegium Pharmaceutical is positioned in the healthcare sector, focusing on innovative therapies and pharmaceuticals, particularly in the pain management space with products like Xtampza ER [1]. Investment Strategy - The analysis emphasizes the importance of identifying companies with breakthrough therapies and potential acquisition catalysts, which is a key focus for investors in the biotech and pharmaceutical industries [1].